Peer-reviewed veterinary case report
How beta3-adrenergic drugs reduce dog fat by activating UCP1
By Omachi, A et al.·Published in Research in veterinary science·2008·Department of Biomedical Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Role of uncoupling protein 1 in the anti-obesity effect of beta3-adrenergic agonist in the dog.
- Species:
- dog
Plain-English summary
A group of beagles was treated with a medication called AJ-9677 to help reduce body fat and improve their metabolism. After two weeks of treatment, researchers found that the dogs' fat cells changed significantly, showing increased energy expenditure and responsiveness to the medication. The treatment led to a seven-fold increase in oxygen consumption in the fat cells, indicating that the medication effectively stimulated fat burning. This suggests that AJ-9677 could be a helpful option for managing obesity in dogs by enhancing their metabolic activity.
People also search for: dog obesity treatment · beagle weight loss medication · AJ-9677 for dogs
Abstract
We have reported that chronic treatment with beta3-adrenoceptor agonists reduces body fat content and induces the expression of mitochondrial thermogenic uncoupling protein 1 (UCP1) in adipose tissue in the dog. To evaluate the role of UCP1 in the anti-obesity effect of the agonists, we isolated adipocytes from subcutaneous fat pad of beagles before and after a 2-week treatment with AJ-9677, a specific beta3-adrenoceptor agonist, and examined their thermogenic activity in vitro. Histological and protein analysis revealed that adipose tissues before the treatment were composed of unilocular cells filled with a single large droplet, while the tissues after the treatment contained many smaller and some multilocular adipocytes expressing UCP1 and abundant mitochondrial proteins. Before the treatment, oxygen consumption rate was very low and did not change even when the cells were stimulated by AJ-9677. Two-week AJ-9677 treatment increased basal oxygen consumption rate by 7-fold, and produced a clear responsiveness to AJ-9677 stimulation. Thus, chronic treatment with AJ-9677 induced UCP1 in adipocytes, where oxygen consumption increased in response to AJ-9677 stimulation. It was suggested that UCP1-dependent energy expenditure in adipose tissue contributes to the anti-obesity effect of beta3-adrenoceptor agonist in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18406437/